The Next Penny Monster

[Tekidesign]

CAMH running!!!

News:
Cambridge Heart Completes Development of New MTWA Module

510(K) Filed with the Food and Drug Administration

TEWKSBURY, Mass., Feb 11, 2010 (BUSINESS WIRE) -- Cambridge Heart, Inc. (OTCBB-
CAMH - News), today announced that the Company has completed the development
phase of its Microvolt T-wave Alternans (MTWA) OEM Module, and has submitted a
510(k) application for regulatory approval with the U.S. Food and Drug
Administration (FDA). The module is the centerpiece of the Company's new business
model that involves partnering with leading stress test equipment manufacturers
to broaden the distribution and use of MTWA technology.

"We are very pleased with our progress and pace in achieving this important
milestone," said Ali Haghighi-Mood, Cambridge Heart's President and CEO. "With
the completion of the development work and our FDA regulatory submission, we are
one step closer to making our Microvolt T-wave Alternans technology available to
more physicians and their patients."

The MTWA test, administered in much the same way as a stress test, is a
non-invasive diagnostic tool that can identify the presence of a subtle
alternating pattern in the ECG which has been shown to be a significant risk
factor for sudden cardiac arrest.

About Cambridge Heart, Inc.

Cambridge Heart develops and commercializes non-invasive diagnostic tests for
cardiac disease, with a focus on identifying those at risk for sudden cardiac
arrest (SCA). The Company's products incorporate proprietary Microvolt T-Wave
Alternans(TM) measurement technologies, including the patented Analytic Spectral
Method(R) and ultrasensitive disposable electrode sensors. The Company's MTWA
test, originally based on research conducted at the Massachusetts Institute of
Technology, is reimbursed by Medicare under its National Coverage Policy.

Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the
Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.

http://www.cambridgeheart.com.

Statements contained in this press release that are not purely historical are
forward-looking statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. In some cases, we use words
such as "believes", "expects", "anticipates", "plans", "estimates", "could", and
similar expressions that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Actual results may differ materially
from those indicated by these forward-looking statements. Factors that may cause
or contribute to such differences include failure to achieve broad market
acceptance of the Company's MTWA technology, failure of our sales and marketing
organization to market our products effectively, inability to hire and retain
qualified clinical applications specialists in the Company's target markets,
failure to obtain or maintain adequate levels of first-party reimbursement for
use of the Company's MTWA test, customer delays in making final buying decisions,
decreased demand for the Company's products, failure to obtain funding necessary
to develop or enhance our technology, adverse results in future clinical studies
of our technology, failure to obtain or maintain patent protection for our
technology and other factors identified in our most recent Annual Report on Form
10-K under "Risk Factors", which is on file with the SEC and available at
http://www.EDGAR.com. In addition, any forward-looking statements represent our
estimates only as of today and should not be relied upon as representing our
estimates as of any subsequent date. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any obligation
to do so except as may be legally necessary, even if our estimates should change.

SOURCE: Cambridge Heart, Inc.

At Cambridge Heart:
Vincenzo LiCausi, 978-654-7600 x 6645
Chief Financial Officer
[e-mail]
or
Media:
KOGS Communication
Edna Kaplan, 781-639-1910
[e-mail]
or
Investor Relations:
Allen & Caron
Matt H. Clawson, 949-474-4300
[e-mail]


Copyright Business Wire 2010